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Abstract
Background:  Anticoagulation with warfarin should be stopped 4–6 days before invasive
procedures to avoid bleeding complications. Despite this routine, some patients still have high
International Normalized Ratio (INR) values on the day of surgery and the procedure may be
cancelled. We sought to identify easily available clinical characteristics that may influence the rate
of normalization of prothrombin time when warfarin is stopped before surgery or invasive
procedures.
Methods: Clinical data were collected retrospectively from consecutive cases from two cohorts,
who stopped warfarin 6 days before surgery. An INR value of 1.6 or higher on the day of surgery
or requirement for reversal with vitamin K the day before surgery were criteria for slow return
(S) to normal INR.
Results: Of 202 patients, 14 (7%) were classified as S. Eight of the S-patients required reversal with
vitamin K one day before surgery and in another case surgery was cancelled due to high INR.
Baseline INR was the only variable significantly associated with classification as S in stepwise logistic
regression analysis (p = 0.003). The odds ratio for being in the normal group was 0.27 (95%
confidence interval 0.12–0.62) for each unit baseline INR increased. The positive predictive value
of baseline INR with a cut off at > 3.0 was only 15% and for INR > 3.5 it was 33%.
Conclusion: Baseline INR, but not the size of the maintenance dose, is associated with the rate
of normalization of prothrombin time after stopping warfarin, but it has limited utility as predictor
in clinical practice. Whenever normal hemostasis is considered crucial for the safety, the INR
should be checked again before the invasive procedure.
Background
With increasing life expectancy, and thereby also increas-
ing prevalence of atrial fibrillation, a larger proportion of
the population is using vitamin K antagonists (VKA). It
has been reported that 36% of patients, 50 to 99 years of
age, with atrial fibrillation are using VKA with a gradual
increase over time [1]. Atrial fibrillation is prevalent in
about 2.3 million people in the United States and one
million are receiving warfarin [2]. In addition, other
important groups of patients, such as those with venous
thromboembolism or mechanical heart valve prosthesis
use VKA.
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Vitamin K antagonists are temporarily stopped to allow
for invasive procedures. Therapeutically active anticoagu-
lation with VKA during total knee arthroplasty (start of
VKA 10 to 14 days preoperatively) was demonstrated to
cause a greater need for blood transfusions and a lower
postoperative hematocrit than a regimen without any
effect of VKA (started the evening before surgery) during
surgery [3]. In this context it is crucial to understand the
rate of decline of the anticoagulant effect when VKA are
discontinued. The normalization of the prothrombin
time, expressed as International Normalized Ratio (INR)
as an indicator of re-establishment of normal hemostasis
depends on the clearance of the VKA but also on the
capacity of the liver to synthesize the coagulation factors
II, VII, IX and X. The latter is also contingent on the avail-
ability of vitamin K.
The clearance of VKA differs widely between the agents,
from a half-life of 10 h for acenocoumarol, via 35 to 45 h
for warfarin and up to 3 to 5 days for phenprocoumon.
The most widely used VKA is warfarin, of which the most
active S-enantiomer is hydroxylated by the hepatic micro-
somal enzyme CYP2C9 and the less active R-enantiomer
is hydroxylated by CYP3A4, CYP1A1 and CYP1A2 [4].
Genetic polymorphisms in the CYP2C9 enzyme have
been reported to affect the dose requirement of warfarin
[4] but may not influence the normalization of pro-
thrombin time after discontinuing warfarin. Instead, as
discussed above, the capacity of the liver, availability of
vitamin K and possibly other factors such as the sensitivity
of the target enzyme VKORC1 [5] are important for regen-
eration of functionally active coagulation factors.
In the guidelines of the American College of Chest Physi-
cians it is recommended to stop warfarin 5 days before
surgery, unless the risk of bleeding is low [6]. In our expe-
rience, after routinely stopping warfarin for 5 days before
surgery, we continue to observe an elevated INR on the
day of surgery, in some patients. In this study we aimed at
identifying easily available clinical factors that may be
helpful to predict a slow normalization of the INR.
Methods
Study design
In this study we retrospectively reviewed the data from
two sources, both consisting of patients seen by the
Thrombosis Service at Hamilton Health Sciences preoper-
atively for bridging of anticoagulation in association with
surgery or invasive procedures. The first source was a
cohort of 119 patients included during 2003 to 2005 in a
study on the residual activity of low-molecular-weight
heparin (LMWH), used for bridging, on the day of sur-
gery. Sixty-seven out of these fulfilled the criteria for inclu-
sion in our study. The second source was the registry of all
patients seen for perioperative bridging during the years
2005 and 2006 (n = 1,600), from which 136 consecutive
eligible patients were included. Cases that were present in
both sources (n = 16) were not included twice. Patients
eligible for inclusion had to be anticoagulated with warfa-
rin for at least one month before the baseline visit, which
was approximately one week before the procedure or sur-
gery. The INR at the baseline visit had to be at least 2.0. We
excluded patients with no INR value obtained on the day
of surgery, which corresponded to about 70% of all
patients. The reason for missing INR value on the day of
surgery was that the surgeon did not request it, because
establishing a normalized INR was not considered crucial
a) for the type of procedure or b) routinely by that sur-
geon. This was therefore not a selection made by us or
based on patient characteristics. Another 10% of patients
had to be excluded due to missing information regarding
concomitant medication or other important variables.
Patients who received vitamin K already at the baseline
visit to insure a low INR at the time of surgery (n = 5) were
excluded.
Data capturing
We retrieved data from the registry of bridged patients at
the Thrombosis Service and from the computerized med-
ical records of the hospital as follows: patient characteris-
tics – age, sex, body mass index (BMI) and information
regarding liver disease based on previous diagnosis and/or
concurrent laboratory results on serum levels of albumin,
bilirubin and liver transaminases; warfarin-related data –
maintenance dose of warfarin (mean, mg/week) during
the month before surgery, baseline INR value, interval
between last dose of warfarin and procedure/surgery, pre-
operative INR value, dose of vitamin K in case of high pre-
operative INR necessitating reversal of warfarin;
concomitant medications; readily available laboratory
data on hemoglobin, serum albumin, bilirubin and creat-
inine.
Definitions and endpoints
The primary endpoint was "slow normalization of pro-
thrombin time" (S) versus "expected normalization" (E).
We defined S-patients as those with an INR of at least 1.6
on the day of surgery or who had INR 1.6 or higher the
day before surgery and were brought back to Thrombosis
Service to receive vitamin K at a dose of at least 1 mg orally
to ensure a sufficiently low INR the following day.
We analyzed for the effect of individual concomitant
drugs that were frequently used and had known interac-
tions with warfarin. A typical example is amiodarone,
which had a high prevalence in our population and has a
well-described profound effect on the clearance of warfa-
rin [7]. Due to the plethora of concomitant medications,
we also created a "medication interaction score" in an
attempt to summarize the effect of medications known toThrombosis Journal 2008, 6:15 http://www.thrombosisjournal.com/content/6/1/15
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interact in a positive or negative way with warfarin. Medi-
cations known to enhance the effect of warfarin (e.g. ami-
odarone) received a positive score and vice versa. We
classified the interacting drugs as having a moderate (1
point) or strong (2 points) effect on the pharmacodynam-
ics of warfarin. This was based partly on the level of evi-
dence for such an interaction according to a recent
systematic overview [8] and partly on our experience of
the magnitude of the interaction. Our final classification
is shown in Table 1. We then added the net effects of all
interacting drugs to produce the "medication interaction
score".
The day of surgery is defined as Day 0, the day before sur-
gery was Day -1 etc. Baseline INR was the value obtained
0 to 2 days before stopping warfarin. The BMI was calcu-
lated from the body weight (kg) divided by the square of
height (m2).
Statistical analysis
In the univariable analysis we used t-test for continuous
data and the Chi square test or Fisher's exact test for bino-
mial data. Variables with a P-value of less than 0.2 for an
effect on the normalization of prothrombin time were
entered into a stepwise logistic regression model. We used
the SAS System, version 9.1 (SAS Institute Inc., Cary, NC,
USA). A P-value of < 0.05 was considered statistically sig-
nificant.
The Research Ethics Board of McMaster University and
Hamilton Health Sciences approved the study as a retro-
spective chart review without need for obtaining informed
consent from the patients.
Results
We identified 202 consecutive patients from 2003 to 2006
that fulfilled the criteria for inclusion in the study. The
characteristics of the patients are described in Table 2.
There were 14 patients (7%) that fulfilled the criteria for
slow normalization of INR, either due to an INR-value of
at least 1.6 on the day of surgery (n = 6) or due to require-
ment for reversal of warfarin with vitamin K the day
before surgery (n = 8). The mean INR on day -1 for those
who were reversed with vitamin K was 1.95. In one case
with an INR of 1.9 on the day of surgery the pacemaker
implantation was postponed for one week.
The highest baseline INR-value was 4.3. Baseline INR
showed a statistically significant association with slow
return to normal hemostasis (p = 0.0004). There was also
a statistical trend to such an association for the mainte-
nance dose of warfarin (p = 0.06) and for serum creatinine
(p = 0.09). Only four patients did not have any concomi-
tant medications, all in the normal group. There was no
effect of concomitant medications such as amiodarone or
thyroid hormone medications, which were used by 15%
and 11%, respectively, of our patient population and have
strong enhancing interactions with warfarin. We therefore
also examined the possible net effect of all concomitant
medications, as assessed with the "medication interaction
score" we had defined, but again no association was
found.
On multivariable stepwise logistic regression model, base-
line INR was significantly associated with slow normaliza-
Table 1: Score awarded to drugs, according to the evidence and 
impact of interaction with warfarin
Enhancement, +1 Enhancement, +2
acetaminophen alcohol
acetylsalicylic acid amiodarone
amoxicillin/clavulanate anabolic steroids
azithromycin cimetidine
celecoxib ciprofloxacin
chloral hydrate clofibrate
citalopram cotrimoxazole
clarithromycin entacapone
dextropropoxyphene erythromycin
disulfiram fenofibrate
diltiazem fluconazole
fluorouracil fluoxetine
fluvastatin isoniazid
fluvoxamine metronidazole
gemcitabine miconazole
interferon phenylbutazone
itraconazole piroxicam
levamisole/fluorouracil propafenone
levofloxacin sulfinpyrazone
omeprazole sulfamethoxazole-
paclitaxel trimetoprim
phenytoin tamoxifen
propranolol thyroid hormone
quinidine voriconazole
ropinirole zileuton
sertraline
simvastatin
tetracycline
tolterodine
tramadol
Inhibition, -1 Inhibition, -2
azathioprine antithyroid drugs
chlordiazepoxide barbiturates
dicloxacillin bosentan
raloxifene carbamazepine
ribavirin cholestyramine
ritonavir dichloralphenazone
sucralfate griseofulvin
mercaptopurine
mesalamine
nafcillin
rifampinThrombosis Journal 2008, 6:15 http://www.thrombosisjournal.com/content/6/1/15
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Table 2: Characteristics of the patients according to rate of normalization of prothrombin time, and warfarin therapy
Characteristics Normal Slow All Uni-variable p-value Multi-variable p-value
N1 8 8 1 4 2 0 2
Sex, males (%) 136(72) 11(79) 147(73) n.s.‡
Age, y* 69.1(± 10.8)
(36–89)
73.4(± 13.2)
(48–93)
69.4(± 11.0)
(36–93)
0.16 0.49
BMI* 29.2(± 5.5)
(17.1–55.1)
29.0(± 4.3)
(22.2–40.1)
29.2(± 5.4)
(17.1–55.1)
n.s
Weekly warfarin dose, mg* 29.7(± 12.3)
(6.25–77)
23.2(± 13.7)
(8.75–57.5)
29.3(± 12.4)
(6.25–77)
0.06 0.20
Baseline INR* 2.6(± 0.5) (2.0–4.2) 3.2(± 0.6) (2.1–4.3) 2.7(± 0.5) (2.0–4.3) 0.0004 0.0021
Day of last dose warfarin* 
(in relation to surgery)
-6.1(± 0.5) (-8 – -5) -6.1(± 0.3) (-7 – -6) -6.1(± 0.5) 
(49–336)  
n.s.
Pre-operative creatinine, 
μmol/L*
104(± 34) (49–336) 120(± 41) (65–196) 105(± 35)  0.09 0.40
Known liver disease (%) 7(3.7) 1(7.1) 8(4.0) n.s.
Medication interaction 
score*
1.5(± 1.3) (-1 – 5) 1.4(± 1.4) (0–4) 1.5(± 1.3) (-1 – 5) n.s.
Number of concomitant 
drugs*
7 (± 3) (0–14) 8 (± 3) (4–16) 7 (± 3) (0–16) n.s.
Amiodarone medication (%) 29(15) 2(14) 31(15) n.s.
Thyroid hormone treatment 
(%)
21(11) 2(14) 23(11) n.s.
Slow normalization with high INR Figure 1
Slow normalization with high INR. Proportion of patients with slow normalization of prothrombin time according to 
baseline INR-value.
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tion of the INR (p = 0.0021) (Table 2). All other variables
entered into the multivariable model lost significance.
The proportion of patients with slow normalization of
prothrombin time according to quintiles of baseline INR
is shown in Fig. 1.
The positive predictive value (PPV) of a high baseline INR
to identify slow normalization of prothrombin time was
40% for a cut-off at INR > 4.0, 33% for a cut-off at INR >
3.5, and 15% for a cut-off at INR > 3.0 but the sensitivity
was low, as illustrated in the receiver operating character-
istics (ROC) curve (Fig. 2).
Discussion
In this study we have shown that 7% of the patients did
not normalize their prothrombin so that the INR
remained above 1.5 on the day of surgery, in spite of dis-
continuing their warfarin medication for 5 days. Of these
cases, one patient had the surgery cancelled and 8 patients
needed to return to the anticoagulant clinic for vitamin K
on the day before surgery. The baseline INR value, i.e. on
the day of stopping warfarin, was the only variable that
was independently associated with a slow return to nor-
mal hemostasis. Age, BMI and dose of warfarin could have
been expected to influence the rate of normalization but
were not independent predictors.
Our results differ somewhat from those published by
Hylek et al [9]. They found that in addition to the baseline
("index") INR also lower maintenance dose of warfarin,
age, decompensated congestive heart failure and active
cancer prolonged the normalization. Their population
was, however, quite different, defined by excessive base-
line INR of > 6.0 and not planned for surgery. Lubetsky et
al observed that the INR at presentation in patients with
excessive anticoagulation was important for the subse-
quent response to reversal with vitamin K [10]. Whitlock
et al observed in a small study of 40 patients with warfarin
discontinued 6.2 ± 1.3 days before surgery, but with half
of them randomized also to receive 5 mg of vitamin K on
the day of cessation, that INR decreased preoperatively to
1.2 ± 0.1 [11]. The only significant predictor for the value
of individual coagulation factor levels was the time point
from cessation.
The recommendation to stop warfarin for 5 days before
surgery [6] is based partly on the findings in a study where
INR levels were followed closely after discontinuation of
warfarin [12]. Interruption of the medication for 4 doses
was sufficient to reach INR of < 1.2 on the day of surgery,
provided that the baseline INR was between 2.0 and 3.0,
but no patient had INR above 3.0 initially.
Our patient population reflects the cardiovascular profile
of our hospital, and the results may not be applicable to
all patients. However, a majority of the patients treated
with warfarin have a history of cardiovascular disease. In
those treated with oral anticoagulants to prevent a stroke
or systemic embolism after mechanical heart valve
replacement or in patients with atrial fibrillation and a
previous stroke, the number of days off anticoagulation
before surgery should be minimized. On the other hand,
many procedures require a satisfactory hemostatic capac-
ity. It is thus of interest to find the optimal number of days
that the patient should be off warfarin before such an
event. The majority of our patients were bridged with ther-
apeutic dose of the LMWH enoxaparin for the last 3 days
before surgery. It has been shown that with the last dose
of LMWH given a mean of 24 h before surgery, a residual
effect with anti-factor Xa-levels between 0.1 and 0.86 IU/
mL may still be measured on the day of surgery in 30% of
patients [13]. A residual effect of the LMWH may cause a
false high INR-value, but this has mainly been observed
with a point-of-care method and not with standard labo-
ratory methods [14]. In our material there was no differ-
ence in use of LMWH between patients with normal or
slow normalization (data not shown).
The large proportion of males in this population may be
a reflection of the cardiovascular profile of the hospital,
but it is actually identical to that described in a large
cohort study [15]. The average maintenance dose of war-
ROC curve on predictability of baseline INR Figure 2
ROC curve on predictability of baseline INR. Receiver 
operating characteristics (ROC) curve for different cut-off 
values, as shown within the graph, of baseline INR to predict 
slow return to normal prothrombin time after 5 days of ces-
sation of warfarin.
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farin was 29.3 mg/week, compared to 5.42 mg/day (37.9
mg/week) in the above-mentioned study, but the mean
age of the patients was 69.4 years in our study compared
to 58 years in the large cohort. The dose of warfarin is
inversely associated with age [16], which may explain the
lower maintenance dose in our population.
In the study by White et al [12], an association between
age and the time of normalization of INR was described.
In our study with about 10 times larger population, we
could not confirm this association.
A retrospective study design may produce results that are
flawed by selection bias. We tried to avoid this by includ-
ing the majority as consecutive patients from a registry of
all those seen by us before surgery. We did not have infor-
mation on nutrition or alternative drugs used by the
patients, so we cannot exclude such effects on the normal-
ization of hemostasis. Another weakness is that we did
not follow warfarin plasma concentration after cessation,
and we are unable to exclude that some patients were
non-adherent and continued to take warfarin against our
instructions. The patients had, however, been evaluated
carefully and educated at the preoperative visit to make
sure they understood all instructions and would manage
self-injections with LMWH.
Our study was not designed to evaluate the effect of the
INR on the risk of bleeding during or after surgery.
Patients who were not tested immediately before usually
had low-risk procedures. Patients with high-risk proce-
dures were tested and the INR corrected whenever it was
too high.
The main limitation of the study is probably that we did
not analyze the genetic polymorphisms of the CYP2C9
and VKORC1 enzymes, due to the fact that no DNA sam-
ples were saved. The routine analysis of these polymor-
phisms would incur additional costs and perhaps a delay
in the preoperative procedures although rapid testing is
now possible. If mandatory genotyping will be widely
adopted, as proposed in the US, the situation will obvi-
ously change. We were hoping to identify predictive clini-
cal factors that could be useful in a busy clinical setting.
Although the baseline INR value was significantly associ-
ated with the time to normalization of prothrombin time,
it was not a sufficiently good predictor due to large over-
lap. A future study should therefore assess the additional
predictive value of CYP2C9 and VKORC1  polymor-
phisms.
Conclusion
In this retrospective analysis of two cohorts with 202
patients discontinuing warfarin 6 days before surgery 14
patients (7%) had an unsatisfactory high INR prior to sur-
gery and 8 of those required reversal with vitamin K. In
multivariable analysis baseline INR, but not maintenance
dose, age, BMI or concomitant medications, was an inde-
pendent predictor of slow normalization of INR.
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